📊 PHBI Key Takeaways
Is Pharmagreen Biotech Inc. (PHBI) a Good Investment?
Pharmagreen Biotech exhibits catastrophic fundamental deterioration with negative stockholders equity of -$2.1M, revenue of merely $1.6K, and net losses of -$390.3K. The company faces critical insolvency with a current ratio of 0.02x and negative free cash flow of -$242.4K, indicating inability to sustain operations or meet obligations.
Why Buy Pharmagreen Biotech Inc. Stock? PHBI Key Strengths
- Positive gross margin of 11.9% demonstrates theoretical pricing capability despite operational collapse
- Minimal recent insider selling activity indicating no ongoing executive liquidation
- Long-term debt of only $31.8K is modest relative to larger liability base
PHBI Stock Risks: Pharmagreen Biotech Inc. Investment Risks
- Negative stockholders equity of -$2.1M indicates technical insolvency and balance sheet impairment
- Critical liquidity crisis with current ratio of 0.02x and cash of only $5.3K against $2.3M liabilities
- Non-viable business model with $1.6K revenue insufficient to cover -$390.3K annual net loss
Key Metrics to Watch
- Stockholders equity trajectory from current -$2.1M to positive solvency threshold
- Operating cash flow stabilization from -$46.3K burn rate to cash flow breakeven
- Revenue materialization from immaterial $1.6K baseline to sustainable operational levels
Pharmagreen Biotech Inc. (PHBI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PHBI Profit Margin, ROE & Profitability Analysis
PHBI vs Services Sector: How Pharmagreen Biotech Inc. Compares
How Pharmagreen Biotech Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pharmagreen Biotech Inc. Stock Overvalued? PHBI Valuation Analysis 2026
Based on fundamental analysis, Pharmagreen Biotech Inc. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pharmagreen Biotech Inc. Balance Sheet: PHBI Debt, Cash & Liquidity
PHBI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pharmagreen Biotech Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.
PHBI Revenue Growth, EPS Growth & YoY Performance
PHBI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | $18.7K | N/A |
| Q2 2023 | N/A | $18.7K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pharmagreen Biotech Inc. Dividends, Buybacks & Capital Allocation
PHBI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pharmagreen Biotech Inc. (CIK: 0001435181)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PHBI
What is the AI rating for PHBI?
Pharmagreen Biotech Inc. (PHBI) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PHBI's key strengths?
Claude: Positive gross margin of 11.9% demonstrates theoretical pricing capability despite operational collapse. Minimal recent insider selling activity indicating no ongoing executive liquidation.
What are the risks of investing in PHBI?
Claude: Negative stockholders equity of -$2.1M indicates technical insolvency and balance sheet impairment. Critical liquidity crisis with current ratio of 0.02x and cash of only $5.3K against $2.3M liabilities.
What is PHBI's revenue and growth?
Pharmagreen Biotech Inc. reported revenue of $1.6K.
Does PHBI pay dividends?
Pharmagreen Biotech Inc. does not currently pay dividends.
Where can I find PHBI SEC filings?
Official SEC filings for Pharmagreen Biotech Inc. (CIK: 0001435181) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PHBI's EPS?
Pharmagreen Biotech Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PHBI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pharmagreen Biotech Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PHBI stock overvalued or undervalued?
Valuation metrics for PHBI: ROE of N/A (sector avg: 16%), net margin of -25,018.4% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy PHBI stock in 2026?
Our dual AI analysis gives Pharmagreen Biotech Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PHBI's free cash flow?
Pharmagreen Biotech Inc.'s operating cash flow is $-46.3K, with capital expenditures of $196.1K. FCF margin is -15,537.1%.
How does PHBI compare to other Services stocks?
Vs Services sector averages: Net margin -25,018.4% (avg: 10%), ROE N/A (avg: 16%), current ratio 0.02 (avg: 1.5).